These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 20588278)
21. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930 [TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S Br J Cancer; 2004 Nov; 91(9):1651-5. PubMed ID: 15494716 [TBL] [Abstract][Full Text] [Related]
23. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416 [TBL] [Abstract][Full Text] [Related]
24. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243 [TBL] [Abstract][Full Text] [Related]
25. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596 [TBL] [Abstract][Full Text] [Related]
26. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700 [TBL] [Abstract][Full Text] [Related]
27. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441 [TBL] [Abstract][Full Text] [Related]
28. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013 [TBL] [Abstract][Full Text] [Related]
29. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633 [TBL] [Abstract][Full Text] [Related]
30. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Kollmannsberger C; Hirte H; Siu LL; Mazurka J; Chi K; Elit L; Walsh W; Sederias J; Doyle A; Eisenhauer EA; Oza AM Ann Oncol; 2012 Jan; 23(1):238-244. PubMed ID: 21447615 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839 [TBL] [Abstract][Full Text] [Related]
32. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058 [TBL] [Abstract][Full Text] [Related]
33. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066 [TBL] [Abstract][Full Text] [Related]
34. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669 [TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317 [TBL] [Abstract][Full Text] [Related]
36. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030 [TBL] [Abstract][Full Text] [Related]
37. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Burris HA; Dowlati A; Moss RA; Infante JR; Jones SF; Spigel DR; Levinson KT; Lindquist D; Gainer SD; Dar MM; Suttle AB; Ball HA; Tan AR Mol Cancer Ther; 2012 Aug; 11(8):1820-8. PubMed ID: 22679111 [TBL] [Abstract][Full Text] [Related]
38. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614 [TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216 [TBL] [Abstract][Full Text] [Related]